Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

Key Takeaways

Pediatric plaque psoriasis lacks sufficient treatment options and long-term safety data, complicating management strategies.
The disease significantly affects children's quality of life and psychosocial development, requiring a holistic management approach.
Off-label use of adult medications in children raises concerns about dosing accuracy and potential adverse effects.
More pediatric-specific clinical trials are needed to develop safe and effective treatment protocols for this population.

A patient suffering from MDD, shares his story and the rapid benefits of patient experience with NMDA-targeted therapy, commenting on the tremendous quality of life benefit.

EP: 1.Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP: 2.Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP: 3.Commentary on Redefining Depression Management with Updated Treatment Strategies

EP: 4.Navigating Non-Response: A Holistic Approach to Patient Care

Now Viewing

EP: 5.Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP: 6.Quantifying Success: Measuring Depth of Treatment Response in MDD

EP: 7.Access Challenges: Bridging Insurance Gaps for MDD Innovations

EP: 8.Examining Molecular Differences in PDE4 Inhibitors in Pediatric Patients with Plaque Psoriasis

Video content above is prompted by the following:

What are the current challenges and unmet needs in the treatment of pediatric plaque psoriasis?